Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats

被引:57
作者
Addy, N [1 ]
Levin, ED [1 ]
机构
[1] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27710 USA
关键词
nicotine; haloperidol; clozapine; risperidone; memory; radial-arm maze;
D O I
10.1016/S0893-133X(02)00327-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Nicotine has been shown in a variety of studies to improve memory performance. The cognitive effects of nicotine are particularly important with regard to schizophrenia. In the current studies nicotine interactions with three different antipsychotic drugs, haloperidol, clozapine and risperidone, were assessed with regard to memory function. Female Sprague-Dawley rats were trained on the radial-arm maze to asymptotic levels of choice accuracy. They were then administered nicotine alone or in combination with haloperidol, clozapine or risperidone. Acute haloperidol (0.04 mg/kg) did not by itself affect memory performance. Co-adininistration of haloperidol with nicotine, however, decreased memory performance compared with nicotine administration in isolation. Acute clozapine (1.25 and 2.5 mg/kg) caused a significant memory impairment, an effect reversed by acute nicotine co-treatment. Risperidone (0,05 mg/kg), like haloperidol, did not by itself affect memory performance. Risperidone co-administration with nicotine, however, did significantly attenuate the improvement caused by nicotine administration in isolation. The similar interaction of haloperidol and risperidone with nicotine may be due to their common action of blocking D-2 receptors, a mechanism of action not shared by clozapine. In contrast to the interaction of nicotine with haloperidol or risperidone, nicotine effectively reversed clozapine-induced memory impairment. These studies demonstrate interactions between nicotine and antipsychotic drugs in terms of memory, which may have important impacts on the treatment of schizophrenia.
引用
收藏
页码:534 / 541
页数:8
相关论文
共 40 条
[1]   ACUTE ADMINISTRATION OF NICOTINE INCREASES THE INVIVO EXTRACELLULAR LEVELS OF DOPAMINE, 3,4-DIHYDROXYPHENYLACETIC ACID AND ASCORBIC-ACID PREFERENTIALLY IN THE NUCLEUS-ACCUMBENS OF THE RAT - COMPARISON WITH CAUDATE-PUTAMEN [J].
BRAZELL, MP ;
MITCHELL, SN ;
JOSEPH, MH ;
GRAY, JA .
NEUROPHARMACOLOGY, 1990, 29 (12) :1177-1185
[2]  
Buccafusco JJ, 1996, DRUG DEVELOP RES, V38, P196, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<196::AID-DDR8>3.0.CO
[3]  
2-H
[4]   THE COMPARATIVE EFFICACY AND LONG-TERM EFFECT OF CLOZAPINE TREATMENT ON NEUROPSYCHOLOGICAL TEST-PERFORMANCE [J].
BUCHANAN, RW ;
HOLSTEIN, C ;
BREIER, A .
BIOLOGICAL PSYCHIATRY, 1994, 36 (11) :717-725
[5]   BLOCKADE OF NICOTINIC RECEPTOR-MEDIATED RELEASE OF DOPAMINE FROM STRIATAL SYNAPTOSOMES BY CHLORISONDAMINE ADMINISTERED IN-VIVO [J].
ELBIZRI, H ;
CLARKE, PBS .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (02) :414-418
[6]   CHARACTERIZATION OF NICOTINIC RECEPTOR-MEDIATED [H-3] DOPAMINE RELEASE FROM SYNAPTOSOMES PREPARED FROM MOUSE STRIATUM [J].
GRADY, S ;
MARKS, MJ ;
WONNACOTT, S ;
COLLINS, AC .
JOURNAL OF NEUROCHEMISTRY, 1992, 59 (03) :848-856
[7]   IMPROVEMENT IN COGNITIVE FUNCTIONS AND PSYCHIATRIC-SYMPTOMS IN TREATMENT-REFRACTORY SCHIZOPHRENIC-PATIENTS RECEIVING CLOZAPINE [J].
HAGGER, C ;
BUCKLEY, P ;
KENNY, JT ;
FRIEDMAN, L ;
UBOGY, D ;
MELTZER, HY .
BIOLOGICAL PSYCHIATRY, 1993, 34 (10) :702-712
[8]   Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain [J].
Hertel, P ;
Nomikos, GG ;
Iurlo, M ;
Svensson, TH .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :74-86
[9]   Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia [J].
Honey, GD ;
Bullmore, ET ;
Soni, W ;
Varatheesan, M ;
Williams, SCR ;
Sharma, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (23) :13432-13437
[10]  
HUGHES JR, 1986, AM J PSYCHIAT, V143, P993